Zura Bio Ltd — fact timeline

Zura Bio Ltd shareholders approved Approval of the Amended and Restated 2023 Zura Bio Limited Equity Incentive Plan at the 2026-06-17 meeting.

“Proposal 3 - Approval of the Amended and Restated 2023 Zura Bio Limited Equity Incentive Plan The Company's shareholders approved the amendment and restatement of the Company's 2023 Equity Incentive Plan. The votes cast were as follows: For Against Abstain Broker Non-Votes 38,850,373 17,403,607 26,663 18,267,509”

Zura Bio Ltd shareholders approved Ratification of the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm. The Company's shareholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain 74,323,697 30,527 193,928”

Zura Bio Ltd shareholders approved Election of eight director nominees at the 2026-06-17 meeting.

“Proposal 1 - Election of Directors. The Company's shareholders elected the Director Nominees as directors of the Company, each to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal. The votes cast were as follows: Nominee For Against Abstain Broker Non-Votes Daniel Becker 55,968,512 291,173 20,958 18,267,509 Mark Eisner 56,209,068 49,466 22,109 18,267,509 Jennifer Jarrett 39,788,639 16,471,044 20,958 18,267,511 Sandeep Kulkarni 56,250,391 8,292 21,960 18,267,509 Amit Munshi 40,229,829 16,027,697 23,115 18,267,511 Ajay Nirula 56,249,212 8,319 23,113 18,267,508 Steven Schoch 56,197,526 61,025 22,093 18,267,508 Parvinder Thiara 55,766,669 490,857 23,115 18,267,511”

Someit Sidhu resigned as Director at Zura Bio Ltd.

“On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026.”

Zura Bio Ltd reported first quarter ended March 31, 2026 results: net income $24.2 million, or $0.22 per share, EPS $0.22 per share.

“Net loss for the first quarter of 2026 was $24.2 million, or $0.22 per share”

Zura Bio Ltd reported full year ended December 31, 2025 results: net income Net loss was $68.7 million for the year ended December 31, 2025, EPS $(1.06) per basic and diluted share.

“Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025”

Zura Bio Ltd entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters valued at approximately $134.6 million (effective 2026-02-24).

“On February 24, 2026, Zura Bio Limited (the “ Company ’) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 18,200,000 Class A ordinary shares”

Zura Bio Ltd issued 8,657,402 Class A ordinary shares of common stock to Athanor Capital.

“the Company agreed to issue to Athanor 8,657,402 Class A ordinary shares, of par value US$0.0001 each, of the Company (the "Athanor Shares")”

Michael Howell departed as Chief Scientific Officer at Zura Bio Ltd.

“On and effective October 15, 2024, Michael Howell, the Chief Scientific Officer of Zura Bio Limited (the “ Company ”), was separated from the Company.”

Zura Bio Ltd reported first quarter 2024 results: net income $7.7 million.

“Net loss for the first quarter of 2024 was $7.7 million”

Zura Bio Ltd reported financial results for full year 2023.

“Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer”

Robert Lisicki was appointed as Director at Zura Bio Ltd.

“Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.”

Robert Lisicki changed role as Chief Executive Officer at Zura Bio Ltd.

“Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.”

Someit Sidhu changed role as Chief Executive Officer at Zura Bio Ltd.

“On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.”

Zura Bio Ltd dismissed Marcum LLP as its auditor.

“Marcum LLP (" Marcum "), the Company’s independent registered public accounting firm prior to the Business Combination, was terminated as of such date”

Zura Bio Ltd engaged WithumSmith+Brown, PC as its auditor.

“On March 29, 2023, Zura Bio Limited (the " Company ") engaged WithumSmith+Brown, PC (" Withum ") as the Company’s independent registered public accounting firm”

Robert Lisicki was appointed as President and Chief Operating Officer at Zura Bio Ltd.

“On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).”

Chris Cabell departed as Chief Medical Officer and Executive Vice President at Zura Bio Ltd.

“On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.”

Dr. Kiran Nistala was appointed as Executive Vice President at Zura Bio Ltd.

“On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023”

Parvinder Thiara was appointed as member of the Board at Zura Bio Ltd.

“On June 22, 2023, the Board appointed Parvinder Thiara to fill the vacancy on and serve as a member of the Board, to serve until the next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.”

Zura Bio Ltd reported financial results for second quarter ended June 30, 2023.

“Zura Bio Limited (the “Company”) issued a press release announcing its second quarter 2023 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.”

Zura Bio Ltd shareholders approved EIP Amendment Proposal - amend 2023 Equity Incentive Plan to increase shares by 5,564,315 at the 2023-06-01 meeting.

“The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 21,822,290 2,726 0”

Zura Bio Ltd shareholders approved Equity Compensation Proposal - issuance and grant of options to Amit Munshi at the 2023-06-01 meeting.

“The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 21,823,616 1,400 0”

Zura Bio Ltd shareholders approved Private Placement Proposal - issuance of Ordinary Shares and Pre-Funded Warrants at the 2023-06-01 meeting.

“The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 18,511,602 481 6”

Zura Bio Ltd entered into License, Development and Commercialization Agreement with Eli Lilly and Company valued at upfront fee of $15,000,000 (effective 2023-04-26).

“Effective April 26, 2023, our subsidiary ZB17 LLC (“ZB17”) entered into a License, Development and Commercialization Agreement (the “License Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which Lilly granted to ZB17 an exclusive (even as to Lilly), payment-bearing license (the “Lilly License”) to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF (“ZB-106”) in the field (meaning all uses including any and all human therapeutic, diagnosis, prevention, amelioration and prophylactic uses) worldwide.”

Zura Bio Ltd entered into Subscription Agreements with certain individual and institutional accredited investors valued at approximately $80 million (effective 2023-04-26).

“On April 26, 2023, Zura Bio Limited (the “Company” or “Zura”) entered into certain subscription agreements (the “Subscription Agreements”) with certain individual and institutional accredited investors (the “Subscribers”) in connection with the sale by the Company (the “Private Placement”) of Class A ordinary shares, par value $0.0001 per share (the “Shares”) and pre-funded warrants (the “Pre-Funded Warrants”)”

Chris Cabell changed role as Chief Medical Officer and Executive Vice President at Zura Bio Ltd.

“Chris Cabell, the Company’s Chief Medical Officer and Executive Vice President, will be taking on Dr. Klassen’s duties going forward.”

Preston Klassen resigned as President and Chief Operating Officer at Zura Bio Ltd.

“On April 6, 2023, Preston Klassen notified Zura Bio Limited (the “Company”) that he intended to resign as the Company’s President and Chief Operating Officer.”

Zura Bio Ltd: The Company ceased being a shell company as a result of the Business Combination (effective 2023-03-20).

“As a result of the Business Combination, the Company ceased being a shell company.”

Zura Bio Ltd: The board of directors approved and adopted a new Code of Ethics and Conduct Policy applicable to all employees, officers, directors, contractors, suppliers, and agents (effective 2023-03-20).

“In connection with the Business Combination, on March 20, 2023, the Company’s board of directors approved and adopted a new Code of Ethics and Conduct Policy applicable to all employees, officers and directors of the Company, as well as all of the Company’s contractors, suppliers, and agents in connection with their work for the Company.”

Zura Bio Ltd: The Second Amended and Restated Memorandum and Articles of Association became effective, incorporating amendments from the Binding Organizational Documents Proposals and Advisory Governance Proposals (effective 2023-03-20).

“The Second Amended and Restated Memorandum and Articles of Association of the Company (the “ Second A&R MAA ”), which became effective on March 20, 2023 and was filed with the Registrar of Companies of the Cayman Islands on March 21, 2023, includes the amendments proposed by the Binding Organizational Documents Proposals and the Advisory Governance Proposals.”

Zura Bio Ltd underwent a change of control involving Zura Bio Holdings Ltd for $165 million in newly issued Company Class A Ordinary Shares (closed 2023-03-20).

“by securityholders of Holdco at the Closing consisted of newly issued Company Class A Ordinary Shares (or options to purchase such shares) with an aggregate value equal to $165 million (the “ Merger Consideration ”). Subject to, and in accordance with, the terms and conditions of the Business Combination Agreement, in connection with the Merger and the”

Zura Bio Ltd amended Waiver Letter with Zura and Hydra (effective 2023-03-08).

“On March 8, 2023, Zura and Hydra signed a limited waiver letter under the Hydra Promissory Note (the “ Waiver Letter ”), pursuant to which Hydra agreed to waive its acceleration right in consideration of Zura paying to Hydra 125% of the Principal Amount (equal to $10,000,000 in the aggregate) on the earlier of December 8, 2023 and five business days after the consummation of the Business Combination.”

Zura Bio Ltd terminated Hydra Promissory Note with Hydra LLC valued at $8 million (effective 2023-03-21).

“Hydra Promissory Note On December 8, 2022, Zura and Hydra LLC, a Cayman Islands limited liability company managed and controlled by Verender Badial and Someit Sidhu (“ Hydra ”), entered into”

Zura Bio Ltd entered into Registration Rights Agreement with Zura, JATT and certain securityholders.

“Zura, JATT and certain securityholders of each of Zura and JATT who received JATT Class A Ordinary Shares pursuant to the Business Combination Agreement, entered into an amended and restated registration and shareholders rights agreement (the “ Registration Rights Agreement ”), which became effective upon the consummation of the Business Combination.”

Zura Bio Ltd entered into Lilly Lock-Up Agreement with Eli Lilly and Company.

“Lilly Lock-Up Agreement Pursuant to the Equity Grant Agreement (the “ JATT Equity Grant Agreement ”) entered into on December 8, 2023, by and between JATT and Eli Lilly and Company (“ Lilly ”),”

Neil Graham was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Jennifer Jarrett was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Steve Schoch was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Garry Neil was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Sandeep Kulkarni was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Amit Munshi was elected as non-employee director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Someit Sidhu was elected as Director at Zura Bio Ltd.

“Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.”

Zura Bio Ltd shareholders approved The Equity Plan Proposal at the 2023-03-16 meeting.

“The Equity Plan Proposal The proposal to ap”

Zura Bio Ltd shareholders approved The Director Appointment Proposal: A proposal to elect, effective as of the consummation of the Business Combination, of Someit Sidhu, Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham as directors and to serve on the Company's board until the expiration of th at the 2023-03-16 meeting.

“The Director Appointment Proposal A proposal to elect, effective as of the consummation of the Business Combination, of Someit Sidhu, Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham as directors and to serve on the Company's board until the expiration of their respective terms and until their respective successors are duly appointed and qualified. Someit Sidhu Votes For Votes Against Abstentions 4,903,764 4,099 0 Amit Munshi Votes For Votes Against Abstentions 4,903,764 4,099 0 Sandeep Kulkarni Votes For Votes Against Abstentions 4,903,764 4,099 0 Garry Neil Votes For Votes Against Abstentions 4,903,764 4,099 0 Steve Schoch Votes For Votes Against Abstentions 4,903,764 4,099 0 Jennifer Jarrett Votes For Votes Against Abstentions 4,903,764 4,099 0 Neil Graham Votes For Votes Against Abstentions 4,903,764 4,099 0”

Zura Bio Ltd shareholders approved Advisory Governance Proposal D: A proposal to provide that shareholders will not be permitted to act by written resolution in lieu of holding a meeting of shareholders; and to eliminate provisions specific to its status as a blank check company. at the 2023-03-16 meeting.

“Advisory Governance Proposal D: A proposal to provide that shareholders will not be permitted to act by written resolution in lieu of holding a meeting of shareholders; and to eliminate provisions specific to its status as a blank check company. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,359,773 548,090 0”

Zura Bio Ltd shareholders approved Advisory Governance Proposal C: A proposal to provide that the alteration, amendment or repeal of the Proposed MAA will require the affirmative vote of the holders of at least two-thirds (662/3%) of the voting power of the then-outstanding shares entitled to vote thereon, voting together as a single at the 2023-03-16 meeting.

“Advisory Governance Proposal C: A proposal to provide that the alteration, amendment or repeal of the Proposed MAA will require the affirmative vote of the holders of at least two-thirds (662∕3%) of the voting power of the then-outstanding shares entitled to vote thereon, voting together as a single class. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”

Zura Bio Ltd shareholders approved Advisory Governance Proposal B: A proposal to require the removal of any director for cause or by the affirmative vote of at least two-thirds (662/3%) of the voting power of all then-outstanding shares of the Company entitled to vote thereon, voting together as a single class. at the 2023-03-16 meeting.

“Advisory Governance Proposal B: A proposal to require the removal of any director for cause or by the affirmative vote of at least two-thirds (662∕3%) of the voting power of all then-outstanding shares of the Company entitled to vote thereon, voting together as a single class. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,359,773 548,090 0”

Zura Bio Ltd shareholders approved Advisory Governance Proposal A: A proposal to provide that subject to the rights of any holders of preferred shares to appoint directors, the number of directors that shall constitute the board shall be as determined from time to time exclusively by the Company board. at the 2023-03-16 meeting.

“Advisory Governance Proposal A: A proposal to provide that subject to the rights of any holders of preferred shares to appoint directors, the number of directors that shall constitute the board shall be as determined from time to time exclusively by the Company board. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”

Zura Bio Ltd shareholders approved Binding Organizational Documents Proposal C: A proposal to adopt the second amended and restated memorandum and articles of association of the Company. at the 2023-03-16 meeting.

“Binding Organizational Documents Proposal C: A proposal to adopt the second amended and restated memorandum and articles of association of the Company. The voting results of the Ordinary Shares were as follows: Votes For Votes Against Abstentions 4,903,764 4,099 0”